Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3

Int J Cancer. 2000 Jan 20;89(1):69-73. doi: 10.1002/(sici)1097-0215(20000120)89:1<69::aid-ijc11>;2-m.


Very few studies have yet addressed the question of the existence and role of lymphagenesis in tumor growth; it is generally overshadowed by the greater emphasis placed on the blood vascular system. Monoclonal antibodies against vascular endothelial-growth-factor receptor 3 (VEGFR3) have been shown to provide a specific antigenic marker for lymphatic endothelium. By comparison with the microvascular count (MVC), we investigated the prognostic value of the microlymphatic count (MLC) in a series of 60 cases of 2-cm-diameter breast carcinomas. The mean value of MVC was 72.5 and of MLC, 40.5. There was no quantitative correlation between these 2 parameters. The MVC but not the MLC had a prognostic value in overall survival. Neither the MLC nor the MVC had any correlation with axillary-lymph-node invasion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / analysis
  • Breast Neoplasms / blood supply
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology*
  • Endothelium, Lymphatic / metabolism*
  • Humans
  • Immunohistochemistry
  • Lymphatic Metastasis
  • Microcirculation
  • Middle Aged
  • Neovascularization, Physiologic
  • Platelet Endothelial Cell Adhesion Molecule-1 / metabolism
  • Prognosis
  • Receptor Protein-Tyrosine Kinases / metabolism*
  • Receptors, Growth Factor / metabolism*
  • Receptors, Vascular Endothelial Growth Factor
  • Survival Analysis


  • Biomarkers
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Receptors, Growth Factor
  • Receptor Protein-Tyrosine Kinases
  • Receptors, Vascular Endothelial Growth Factor